{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T01:40:21Z","timestamp":1774057221264,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Alvotech Swiss AG"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s40259-025-00748-8","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T10:43:23Z","timestamp":1762166603000},"page":"135-149","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and Safety of Biosimilar AVT05 Versus Reference Product Golimumab in Combination with Methotrexate in Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results of a Randomized, Parallel-Group, Double-Blind Study"],"prefix":"10.1007","volume":"40","clinical-trial-number":[{"clinical-trial-number":"nct05842213","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Monica","family":"Luque","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Zhelyazkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laxmikant","family":"Vashishta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masna","family":"Rai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abid","family":"Sattar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarina","family":"Petrovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Bucknall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffen","family":"Leutz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7684-1792","authenticated-orcid":false,"given":"Fausto","family":"Berti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"issue":"2","key":"748_CR1","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","volume":"117","author":"D Tracey","year":"2008","unstructured":"Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117(2):244\u201379. https:\/\/doi.org\/10.1016\/j.pharmthera.2007.10.001.","journal-title":"Pharmacol Ther"},{"issue":"4","key":"748_CR2","doi-asserted-by":"publisher","first-page":"282","DOI":"10.4103\/injr.injr_210_22","volume":"18","author":"BD Pandey","year":"2023","unstructured":"Pandey BD, Krishnamurthy V, Kumar U, et al. Safety and efficacy of golimumab in rheumatoid arthritis: a prospective, multicenter, real-world study from India. Indian J Rheumatol. 2023;18(4):282\u20138. https:\/\/doi.org\/10.4103\/injr.injr_210_22.","journal-title":"Indian J Rheumatol"},{"issue":"3","key":"748_CR3","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen JS, Landew\u00e9 R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492\u2013509. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204573.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"748_CR4","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1111\/1756-185x.12723","volume":"19","author":"Z Li","year":"2016","unstructured":"Li Z, Zhang F, Kay J, et al. Efficacy and safety results from a phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy. Int J Rheum Dis. 2016;19(11):1143\u201356. https:\/\/doi.org\/10.1111\/1756-185x.12723.","journal-title":"Int J Rheum Dis"},{"issue":"4","key":"748_CR5","doi-asserted-by":"publisher","first-page":"428","DOI":"10.4161\/mabs.12304","volume":"2","author":"DJ Shealy","year":"2010","unstructured":"Shealy DJ, Cai A, Staquet K, et al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor \u03b1. MAbs. 2010;2(4):428\u201339. https:\/\/doi.org\/10.4161\/mabs.12304.","journal-title":"MAbs"},{"issue":"3","key":"748_CR6","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1517\/17425255.2016.1146682","volume":"12","author":"Y Tanaka","year":"2016","unstructured":"Tanaka Y, Senoo A, Fujii H, et al. Evaluation of golimumab for the treatment of patients with active rheumatoid arthritis. Expert Opin Drug Metab Toxicol. 2016;12(3):319\u201326. https:\/\/doi.org\/10.1517\/17425255.2016.1146682.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"6","key":"748_CR7","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1136\/ard.2008.099010","volume":"68","author":"EC Keystone","year":"2009","unstructured":"Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor \u03b1 given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis. 2009;68(6):789\u201396. https:\/\/doi.org\/10.1136\/ard.2008.099010.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"748_CR8","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1002\/art.23969","volume":"58","author":"RD Inman","year":"2008","unstructured":"Inman RD, Davis JC Jr, Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 2008;58(11):3402\u201312. https:\/\/doi.org\/10.1002\/art.23969.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"748_CR9","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1002\/art.34436","volume":"64","author":"A Kavanaugh","year":"2012","unstructured":"Kavanaugh A, van der Heijde D, McInnes IB, et al. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum. 2012;64(8):2504\u201317. https:\/\/doi.org\/10.1002\/art.34436.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"748_CR10","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1002\/art.39257","volume":"67","author":"J Sieper","year":"2015","unstructured":"Sieper J, van der Heijde D, Dougados M, et al. A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2015;67(10):2702\u201312. https:\/\/doi.org\/10.1002\/art.39257.","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"748_CR11","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1136\/annrheumdis-2014-205862","volume":"74","author":"A Deodhar","year":"2015","unstructured":"Deodhar A, Braun J, Inman RD, et al. Golimumab administered subcutaneously every 4\u2005weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study. Ann Rheum Dis. 2015;74(4):757\u201361. https:\/\/doi.org\/10.1136\/annrheumdis-2014-205862.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"748_CR12","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/acr.22759","volume":"68","author":"P Emery","year":"2016","unstructured":"Emery P, Fleischmann RM, Strusberg I, et al. Efficacy and safety of subcutaneous golimumab in methotrexate-naive patients with rheumatoid arthritis: five-year results of a randomized clinical trial. Arthritis Care Res (Hoboken). 2016;68(6):744\u201352. https:\/\/doi.org\/10.1002\/acr.22759.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"9","key":"748_CR13","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1136\/annrheumdis-2013-204902","volume":"73","author":"A Kavanaugh","year":"2014","unstructured":"Kavanaugh A, McInnes IB, Mease P, et al. Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). Ann Rheum Dis. 2014;73(9):1689\u201394. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204902.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"748_CR14","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3899\/jrheum.150712","volume":"43","author":"EC Keystone","year":"2016","unstructured":"Keystone EC, Genovese MC, Hall S, et al. Safety and efficacy of subcutaneous golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: final 5-year results of the GO-FORWARD trial. J Rheumatol. 2016;43(2):298\u2013306. https:\/\/doi.org\/10.3899\/jrheum.150712.","journal-title":"J Rheumatol"},{"issue":"9685","key":"748_CR15","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/s0140-6736(09)60506-7","volume":"374","author":"JS Smolen","year":"2009","unstructured":"Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor \u03b1 inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet. 2009;374(9685):210\u201321. https:\/\/doi.org\/10.1016\/s0140-6736(09)60506-7.","journal-title":"Lancet"},{"key":"748_CR16","unstructured":"European Medicines Agency (EMA). Simponi: summary of product characteristics Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/simponi-epar-product-information_en.pdf. Accessed 18 Jun 2025."},{"key":"748_CR17","unstructured":"US Food and Drug Administration (FDA) Simponi: US prescibing information. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/125289s155,125433s036lbl.pdf. Accessed 18 Jun 2025."},{"key":"748_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2021.11.009","volume":"52","author":"TK Kvien","year":"2022","unstructured":"Kvien TK, Patel K, Strand V. The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems. Semin Arthritis Rheum. 2022;52:151939. https:\/\/doi.org\/10.1016\/j.semarthrit.2021.11.009.","journal-title":"Semin Arthritis Rheum"},{"issue":"11","key":"748_CR19","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1007\/s00198-024-07161-x","volume":"35","author":"JY Reginster","year":"2024","unstructured":"Reginster JY, Czerwinski E, Wilk K, et al. Efficacy and safety of candidate biosimilar CT-P41 versus reference denosumab: a double-blind, randomized, active-controlled, phase 3 trial in postmenopausal women with osteoporosis. Osteoporos Int. 2024;35(11):1919\u201330. https:\/\/doi.org\/10.1007\/s00198-024-07161-x.","journal-title":"Osteoporos Int"},{"key":"748_CR20","unstructured":"European Medicines Agency (EMA). Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1). Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active-substance-quality-issues-revision-1_en.pdf. Accessed 18 Jun 2025."},{"issue":"6","key":"748_CR21","doi-asserted-by":"publisher","first-page":"e1951","DOI":"10.1210\/clinem\/dgae611","volume":"110","author":"B Langdahl","year":"2025","unstructured":"Langdahl B, Chung YS, Plebanski R, et al. Proposed denosumab biosimilar SB16 vs reference denosumab in postmenopausal osteoporosis: phase 3 results up to month 12. J Clin Endocrinol Metab. 2025;110(6):e1951\u20138. https:\/\/doi.org\/10.1210\/clinem\/dgae611.","journal-title":"J Clin Endocrinol Metab"},{"key":"748_CR22","unstructured":"US Food and Drug Administration (FDA). Scientific considerations in demonstrating biosimilarity to a reference product. Available from: https:\/\/www.fda.gov\/media\/82647\/download. Accessed 18 Jun 2025."},{"key":"748_CR23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2147\/ceor.s12494","volume":"3","author":"S Simoens","year":"2011","unstructured":"Simoens S. Biosimilar medicines and cost-effectiveness. Clinicoecon Outcomes Res. 2011;3:29\u201336. https:\/\/doi.org\/10.2147\/ceor.s12494.","journal-title":"Clinicoecon Outcomes Res."},{"issue":"Suppl. 1","key":"748_CR24","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1136\/annrheumdis-2024-eular.1949","volume":"83","author":"C Wynne","year":"2024","unstructured":"Wynne C, Lorch U, Krantz E, et al. AB0516 A pharmacokinetic (PK) similarity study between AVT05 and reference product golimumab. Ann Rheum Dis. 2024;83(Suppl. 1):1530. https:\/\/doi.org\/10.1136\/annrheumdis-2024-eular.1949.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"748_CR25","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1093\/rheumatology\/keg072","volume":"42","author":"JS Smolen","year":"2003","unstructured":"Smolen JS, Breedveld FC, Schiff MH, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford). 2003;42(2):244\u201357. https:\/\/doi.org\/10.1093\/rheumatology\/keg072.","journal-title":"Rheumatology (Oxford)"},{"key":"748_CR26","unstructured":"National Institutes of Health. CTCAE and adverse event reporting 2025. Available from: https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events. Accessed 28 Oct 2025."},{"issue":"6","key":"748_CR27","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1136\/ard.2007.084459","volume":"68","author":"G Wells","year":"2009","unstructured":"Wells G, Becker JC, Teng J, et al. Validation of the 28-joint disease activity score (DAS28) and European league against rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis. 2009;68(6):954\u201360. https:\/\/doi.org\/10.1136\/ard.2007.084459.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"748_CR28","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1208\/s12248-016-9878-1","volume":"18","author":"B Gorovits","year":"2016","unstructured":"Gorovits B, Clements-Egan A, Birchler M, et al. Pre-existing antibody: biotherapeutic modality-based review. AAPS J. 2016;18(2):311\u201320. https:\/\/doi.org\/10.1208\/s12248-016-9878-1.","journal-title":"AAPS J"},{"issue":"4","key":"748_CR29","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1080\/19420862.2015.1048411","volume":"7","author":"KA van Schie","year":"2015","unstructured":"van Schie KA, Gerrit-Jan W, Rispens T. Cross-reactive and pre-existing antibodies to therapeutic antibodies: effects on treatment and immunogenicity. MAbs. 2015;7(4):662\u201371. https:\/\/doi.org\/10.1080\/19420862.2015.1048411.","journal-title":"MAbs"},{"issue":"6","key":"748_CR30","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1208\/s12248-017-0153-x","volume":"19","author":"L Xue","year":"2017","unstructured":"Xue L, Clements-Egan A, Amaravadi L, et al. Recommendations for the assessment and management of pre-existing drug-reactive antibodies during biotherapeutic development. AAPS J. 2017;19(6):1576\u201386. https:\/\/doi.org\/10.1208\/s12248-017-0153-x.","journal-title":"AAPS J"},{"issue":"1","key":"748_CR31","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/biologics5010006","volume":"5","author":"SS Aljahili","year":"2025","unstructured":"Aljahili SS, Alshuwairikh SS, AlKhaldi A, et al. Safety of switching from a reference biologic to its biosimilar: a systematic review and meta-analysis. Biologics. 2025;5(1):6. https:\/\/doi.org\/10.3390\/biologics5010006.","journal-title":"Biologics"},{"issue":"4","key":"748_CR32","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s40265-018-0881-y","volume":"78","author":"HP Cohen","year":"2018","unstructured":"Cohen HP, Blauvelt A, Rifkin RM, et al. Switching reference medicines to biosimilars: a systematic literature review of clinical outcomes. Drugs. 2018;78(4):463\u201378. https:\/\/doi.org\/10.1007\/s40265-018-0881-y.","journal-title":"Drugs"},{"issue":"10","key":"748_CR33","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1016\/j.drudis.2019.06.016","volume":"24","author":"HC Ebbers","year":"2019","unstructured":"Ebbers HC, Schellekens H. Are we ready to close the discussion on the interchangeability of biosimilars? Drug Discov Today. 2019;24(10):1963\u20137. https:\/\/doi.org\/10.1016\/j.drudis.2019.06.016.","journal-title":"Drug Discov Today"},{"key":"748_CR34","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2147\/btt.s124476","volume":"11","author":"JR Tesser","year":"2017","unstructured":"Tesser JR, Furst DE, Jacobs I. Biosimilars and the extrapolation of indications for inflammatory conditions. Biologics. 2017;11:5\u201311. https:\/\/doi.org\/10.2147\/btt.s124476.","journal-title":"Biologics"},{"key":"748_CR35","unstructured":"US Food and Drug Administration (FDA). Biosimilar product regulatory review and approval. Available from: https:\/\/www.fda.gov\/files\/drugs\/published\/Biosimilar-Product-Regulatory-Review-and-Approval.pdf. Accessed 18 Jun 2025."},{"issue":"20","key":"748_CR36","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1182\/blood-2014-06-583617","volume":"124","author":"M Weise","year":"2014","unstructured":"Weise M, Kurki P, Wolff-Holz E, et al. Biosimilars: the science of extrapolation. Blood. 2014;124(20):3191\u20136. https:\/\/doi.org\/10.1182\/blood-2014-06-583617.","journal-title":"Blood"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-025-00748-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-025-00748-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-025-00748-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T07:13:23Z","timestamp":1768029203000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-025-00748-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["748"],"URL":"https:\/\/doi.org\/10.1007\/s40259-025-00748-8","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"assertion":[{"value":"7 October 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Monica Luque, Kristina Zhelyazkova, Laxmikant Vashishta, Masna Rai, Abid Sattar, Richard Bucknall, Steffen Leutz, and Fausto Berti\u00a0are employees at Alvotech. Katarina Petrovic was an employee of Alvotech at the time of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki, the International Council for Harmonisation Good Clinical Practice guidelines, and the appropriate regulatory requirements in the countries in which the study was conducted.\u00a0The protocol, its amendments, and informed consent documentation were reviewed and approved by the institutional review board(s) or independent ethics committee(s) at each study site.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All participants gave written informed consent to participate in the study prior to undertaking any study-related examination or activity. The informed consent document was approved by each study site\u2019s institutional review board or independent ethics committee.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The datasets generated and\/or analyzed during the current study are available from the sponsor on reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors were involved in the conception and design of the study. KZ and RB were involved in the provision of study materials and patients and acquisition of the data. ML, LV, MR, AB, SL, and FB performed the analysis and\/or the interpretation of the data. All authors revised the report critically. All authors approved the final version.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}